No Data
INNOCARE (09969.HK) spent 1.729 million HKD to repurchase 0.3 million shares on January 24.
On January 24, Gelonghui reported that INNOCARE (09969.HK) announced it spent 1.729 million Hong Kong dollars to repurchase 0.3 million shares on January 24, 2025, at a repurchase price of 5.64-5.82 Hong Kong dollars per share.
[Brokerage Focus] CMB International maintains a Buy rating on INNOCARE (09969) and stated that the self-immune pipeline will further drive business growth.
Jinwu Financial News | Zhainan International reports that INNOCARE (09969) will further drive Business growth with autoimmune pipelines. Obrutinib achieved strong sales growth in 2024, increasing by 49% year-on-year, reaching 1.001 billion yuan, exceeding the company's growth guidance of 45%. The bank expects Obrutinib to continue achieving strong sales in the oncology market. At the same time, INNOCARE's progress in the autoimmune disease field is also noteworthy, including Obrutinib in multiple sclerosis (MS), ICP-332 (TYK-2JH1) in atopic dermatitis (AD) and ICP-488 (
INNOCARE (09969.HK) spent HKD 2.2532 million to repurchase 0.4 million shares on January 23.
Gelonghui reported on January 23 that INNOCARE (09969.HK) announced the repurchase of 0.4 million shares at a cost of 2.2532 million Hong Kong dollars on January 23, 2025, with a repurchase price of 5.57-5.76 Hong Kong dollars per share.
INNOCARE (09969.HK) spent 2.4395 million Hong Kong dollars to repurchase 0.426 million shares on January 22.
Gelonghui reported on January 22 that INNOCARE (09969.HK) announced that on January 22, 2025, it spent 2.4395 million Hong Kong dollars to repurchase 0.426 million shares, with the repurchase price per share being 5.66-5.74 Hong Kong dollars.
InnoCare Pharma Appoints Renowned Scientist as Independent Director
InnoCare Pharma Updates Board of Directors and Roles
